Status:

UNKNOWN

SPHERIC-1. Sildenafil and Pulmonary HypERtension In COPD

Lead Sponsor:

Italian Association of Hospital Pneumologists

Conditions:

Pulmonary Hypertension

COPD

Eligibility:

All Genders

18-80 years

Phase:

PHASE3

Brief Summary

Although pulmonary hypertension (PH) is a quite frequent complication of advanced pulmonary diseases, and it is an independent prognostic factor, until now no evidence-based treatment approach exists ...

Eligibility Criteria

Inclusion

  • Patient affected by stable COPD under optimal treatment, chronic oxygen therapy in patients with hypoxia, with PaO2 at rest ≥ 60 mmHg and PaCO2≤ 55 mmHg, aged between 18 and 80 years old:
  • Group 1: BPCO GOLD I-III (post bronchodilator FEV1 ≥ 30%, FEV1/FVC ≤ 0,7 , TLC ≥ 70%) + PAPm ≥ 30 mmHg and PCP \<15 mmHg
  • Group 2: BPCO GOLD IV (post bronchodilator FEV1 \<30%, FEV1/FVC ≤ 0,7 , TLC ≥ 70%) + PAPm ≥ 35 mmHg and PCP \<15 mmHg

Exclusion

  • Different types of pulmonary hypertension (chronic, thromboembolic pulmonary hypertension, pulmonary arterial hypertension etc.)
  • Significant left cardiac disease (LVEF \<45%, cardiomyopathy, valvulopathy, unstable coronaropathy)
  • Treatment with nitrates in the last 10 days, or in need of other nitrate therapy for different diseases
  • Treatment with other specific drugs for arterial pulmonary hypertension (less than 4 weeks)
  • Significant systemic disease other than COPD
  • Recent exacerbations of chronic bronchitis (\< 4 weeks)
  • Pregnancy or breastfeeding, or women without an adequate contraceptive method for the whole study duration
  • History of anaphylaxis or allergic reactions to 5-phosphodiesterase inhibitors
  • Cancers within the last 5 years with the exception of localized cancers of the skin or of the cervix
  • Hepatic insufficiency or chronic renal failure or hemoglobinemia \< 10 g/dL during the screening phase
  • Contraindications to subministration as per SPC
  • Mental disorder, alcohol abuse, chronic alcoholism, drug abuse
  • Subjects unable to sign the informed consent form
  • Subjects unable to walk

Key Trial Info

Start Date :

October 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 1 2013

Estimated Enrollment :

32 Patients enrolled

Trial Details

Trial ID

NCT01441934

Start Date

October 1 2010

End Date

February 1 2013

Last Update

February 4 2013

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

Pulmonary Unit - Azienda Ospedaliera Ospedale Niguarda Ca' Granda

Milan, Milano, Italy, 20162

2

Pulmonary Diseases Clinic - Azienda Ospedaliera Universitaria - Policlinico di Modena

Modena, Modena, Italy, 41100

3

Pulmonary Clinic - Federico II University - Azienda Ospedaliera V. Monaldi

Napoli, Napoli, Italy, 80131

4

Thoracic Surgery Clinic - Azienda Ospedaliera di Padova

Padua, Padova, Italy, 35128

SPHERIC-1. Sildenafil and Pulmonary HypERtension In COPD | DecenTrialz